Nucleai secures a $14 million investment from M Ventures to advance its spatial AI biomarker technology, enhancing patient enrollment in clinical trials and driving innovation in personalized medicine.

Target Information

Nucleai is a pioneering company in the field of spatial AI biomarkers, with a specific focus on deciphering cellular interactions within tissue samples to improve the prediction of therapeutic outcomes. Recently, Nucleai has secured a $14 million investment, led by M Ventures, the corporate venture arm of Merck KGaA in Darmstadt, Germany. This funding contributes to a total of $60 million to date and will enable Nucleai to enhance its AI algorithms, facilitating the prospective enrollment of patients in clinical trials—a groundbreaking step for personalized medicine.

The company has demonstrated significant momentum, engaging in collaborations with more than 60 percent of the top 20 biopharmaceutical firms and receiving support from prominent investors such as Section 32 and Sanofi Ventures. Nucleai’s innovative technology transforms static biopsy samples into dynamic, AI-driven action plans that provide pathologists with the insights needed to address complex diseases like cancer more effectively.

Industry Overview in Israel

The life sciences industry in Israel is thriving, characterized by a strong emphasis on research and development. Israel has emerged as a global hub for biotech innovation, supported by a rich ecosystem of universit